Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;9(2):e002220.
doi: 10.1136/jitc-2020-002220.

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology

Berna C Özdemir  1   2
Affiliations

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology

Berna C Özdemir. J Immunother Cancer. 2021 Feb.

Abstract

Despite a significant amount of data on incidence and therapy of immune-related adverse events affecting virtually all organ systems, the potential impact of immune checkpoint inhibitors (ICIs) on gonadal function has not been sufficiently studied. The limited evidence available suggests that ICI-related primary hypogonadism due to orchitis as well as secondary hypogonadism due to hypophysitis are a potential risk for infertility. A systematic investigation of gonadal function under ICIs is warranted given the increasing application of ICIs in the adjuvant setting, among young adults and children and the possible influence of sex hormone levels on the efficacy and toxicity of ICIs.

Keywords: immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019;2:e192535. 10.1001/jamanetworkopen.2019.2535 - DOI - PMC - PubMed
    1. Martins F, Sofiya L, Sykiotis GP, et al. . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–80. 10.1038/s41571-019-0218-0 - DOI - PubMed
    1. Nogueira E, Newsom-Davis T, Morganstein DL. Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Ther Adv Endocrinol Metab 2019;10:2042018819896182. 10.1177/2042018819896182 - DOI - PMC - PubMed
    1. Bai X, Lin X, Zheng K, et al. . Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the who adverse drug reaction database, VigiBase. Endocrine 2020;69:670–81. 10.1007/s12020-020-02355-9 - DOI - PMC - PubMed
    1. Garon-Czmil J, Petitpain N, Rouby F, et al. . Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database. Sci Rep 2019;9:19419. 10.1038/s41598-019-56026-5 - DOI - PMC - PubMed

MeSH terms

Substances